We’re with you
Anovo’s patients are our first priority
We’ve built our unique care management model to ensure that you have constant and consistent access to the therapies you need and experts to help guide you through your therapeutic journey.
Meet some of our patients and hear their stories about how we help.
We understand the hurdles you face as a rare disease patient or caregiver
You’re one of an estimated 300 million people worldwide facing these challenges, but you have unique needs. There are so many rare diseases that medical expertise and therapeutic support for each is hard to find. That’s why we’ve dedicated ourselves to exclusively and comprehensively filling this gap.
patient satisfaction ratings over 7 years
patient adherence through 90 days
"Every step of the way has been simple and easy to navigate thanks to the hard work and kindness of every employee I’ve spoken to. Thank you!"
"The staff at Anovo have exceeded my expectations. They go above and beyond for their clients. They have great customer service, and have always treated me with the utmost respect and kindness. Thank you!"
We tailor our care to each patient’s unique situation
Providing comprehensive care and support requires focused dedication and customization for every patient we serve
With your personal Care Coordinator as the point person, all patient services are coordinated for you, including collaboration with our own, in-house reimbursement specialists and specialty pharmacy
Our insurance experts make sure you get coverage fast and begin therapy quickly, without financial anxiety
And because we also manage every step of the medication delivery chain – from the point of manufacture to your door – you never need to worry about running out of the medications you depend on
When you have questions or concerns, or your situation changes, we encourage you call your Care Coordinator right away. That’s why we’re here
ANASCORP is an antivenom indicated for treatment of clinical signs of scorpion envenomation.
ALKINDI SPRINKLE is a corticosteroid indicated as replacement therapy in pediatric patients with adrenocortical insufficiency.
Carglumic Acid tablets for oral suspension are indicated in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency; and maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency.
CYSTADANE is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations.
CYSTADROPS is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.
DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
SIGNIFOR is a somatostatin analog indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
SIGNIFOR LAR is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/ or for whom surgery is not an option; and for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.